Stroke, IschemicNCT04607070
Ischemic Strokes While on NOAC - How Compliance Matters
An observational study of Stroke, Ischemic and Stroke, Acute, run by Chinese University of Hong Kong at 1 site in Hong Kong.
Trial summary
This study is aimed to depict the epidemiological trend, aetiologies, clinical characteristics, treatment options of IS-NOAC in face of the rapidly increasing NOAC usage. Knowledge on this ischaemic stroke entity will define clinical characteristics, identify preventable causes and inform resource allocation on the… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Stroke, Ischemic, Stroke, Acute, Stroke Syndrome
- How many people
- 91 participants
- Where
- 1 siteHong Kong
- Study dates
- 1 Oct 2020to 30 Jun 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with known AF who developed ischaemic stroke or TIA and admitted in the Prince of Wales Hospital in years 2010, 2012, 2014, 2016 and 2018 will be recruited into this study
Who may be able to join
- Patients who were ethnic Chinese
- Patients with known AF
- Patient who suffered from ischaemic stroke
Who cannot join
- Patient who are non-ethnic Chinese
- Patient who suffered from haemorrhagic stroke
Trial locations and contacts
1 site in 1 country.
About this study
This study is aimed to depict the epidemiological trend, aetiologies, clinical characteristics, treatment options of IS-NOAC in face of the rapidly increasing NOAC usage. Knowledge on this ischaemic stroke entity will define clinical characteristics, identify preventable causes and inform resource allocation on the evaluation modalities, reperfusion strategies and forecast future burden of IS-NOAC.
Read the detailed description
Data will be retrieved from the stroke registry of Prince of Wales Hospital which recorded all in- and out-patients with stroke or transient ischaemic attack (TIA). All consecutive adult patients with known AF who developed ischaemic stroke or TIA in 2010, 2012, 2014, 2016 and 2018 (i.e. 5 full yearly time-points) and categorize the patients according to their anticoagulation status (elaborated below) with the inclusion and exclusion criteria stated will be recruited.
All demographic data, blood results, imaging and assessment data will be retrieved from electronic patient record (CMS system) and stroke registry. All-cause mortality at 1 year will be verified via CMS system too.
- Conditions
- Stroke, Ischemic, Stroke, Acute, Stroke Syndrome, Stroke, Cardiovascular, Atherosclerosis, Ischemic Stroke
- Keywords
- stroke, NOAC
- Medical subject headings
- Ischemic Stroke, Stroke, Myocardial Infarction, Atherosclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Stroke patient | This is a registry-based study that will involve consecutive adult patients with known AF who developed ischaemic stroke or TIA in years 2010, 2012, 2014, 2016 and 2018. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Compliance affects the outcomes of ischemic stroke during NOAC usage.
To depict epidemiological trend and aetiologies on different dosage of NOAC in stroke patients.
Measured: 30 Sept 2021
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Oct 2020
- Study start1 Oct 2020
- Primary completion30 Jun 2025
- Study completion30 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Stroke, IschemicStudies of the same condition, open and under way.
- More trials run by Chinese University of Hong KongThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 91 participants (actual)
Sponsor and investigators
- Lead sponsor
- Chinese University of Hong Kong
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr. IP Yiu Ming Bonaventure, Chinese University of Hong Kong
- Investigators
- Yiu Ming Bonaventure IP, MBChB, MRCP, Principal investigator, Chinese University of Hong Kong
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04607070
- Sponsor's protocol ID
- Crec 2020.427
- Status last verified
- Feb 2026
- First submitted
- 23 Oct 2020
- Last updated
- 24 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ischemic Strokes While on NOAC - How Compliance Matters
- ClinicalTrials.gov ID
- NCT04607070
- Acronym / sponsor ID
- Crec 2020.427
- Conditions
- Stroke, Ischemic, Stroke, Acute, Stroke Syndrome, Stroke, Cardiovascular, Atherosclerosis, Ischemic Stroke
- Keywords
- stroke, NOAC
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 91 participants (actual)
- Lead sponsor
- Chinese University of Hong KongUniversity, hospital or other
- Study start
- 1 Oct 2020 (actual)
- Primary completion
- 30 Jun 2025 (actual)
- Study completion
- 30 Jun 2025 (actual)
- First posted
- 28 Oct 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is aimed to depict the epidemiological trend, aetiologies, clinical characteristics, treatment options of IS-NOAC in face of the rapidly increasing NOAC usage. Knowledge on this ischaemic stroke entity will define clinical characteristics, identify preventable causes and inform resource allocation on the evaluation modalities, reperfusion strategies and forecast future burden of IS-NOAC.
Detailed description
Data will be retrieved from the stroke registry of Prince of Wales Hospital which recorded all in- and out-patients with stroke or transient ischaemic attack (TIA). All consecutive adult patients with known AF who developed ischaemic stroke or TIA in 2010, 2012, 2014, 2016 and 2018 (i.e. 5 full yearly time-points) and categorize the patients according to their anticoagulation status (elaborated below) with the inclusion and exclusion criteria stated will be recruited.
All demographic data, blood results, imaging and assessment data will be retrieved from electronic patient record (CMS system) and stroke registry. All-cause mortality at 1 year will be verified via CMS system too.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Stroke patient | – | –This is a registry-based study that will involve consecutive adult patients with known AF who developed ischaemic stroke or TIA in years 2010, 2012, 2014, 2016 and 2018. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with known AF who developed ischaemic stroke or TIA and admitted in the Prince of Wales Hospital in years 2010, 2012, 2014, 2016 and 2018 will be recruited into this study
Key inclusion criteria (3 listed)
- Patients who were ethnic Chinese
- Patients with known AF
- Patient who suffered from ischaemic stroke
Key exclusion criteria (2 listed)
- Patient who are non-ethnic Chinese
- Patient who suffered from haemorrhagic stroke
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Compliance affects the outcomes of ischemic stroke during NOAC usage.
Time frame: 30 Sept 2021
To depict epidemiological trend and aetiologies on different dosage of NOAC in stroke patients.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Stroke, Ischemic
Not yet recruitingPhase 3
Metformin in Acute Ischemic Stroke
Acute Ischemic Stroke
Not yet recruiting
Safety of NRICM301 Added to Standard Care in Adults With Acute Ischemic Stroke
Acute Ischemic Stroke
Not yet recruitingPhase 2/3
A Phase II/III Clinical Study of SIM0811 in the Treatment of Acute Ischemic Stroke
Acute Ischemic Stroke AIS
Not yet recruitingObservational study
The GEIR (Grupo español de Ictus Retina) Registry: Rationale and Design of the First Nationwide Multicentre Retinal Stroke Registry in Spain
Retinal Artery Occlusion, Central Retinal Artery Occlusion
RecruitingPhase 3
Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2
Acute Ischemic Stroke
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yiu Ming Bonaventure IP, MBChB, MRCP principal investigator
Chinese University of Hong Kong
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Stroke, Ischemic and Stroke, Acute, run by Chinese University of Hong Kong at 1 site in Hong Kong.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compliance affects the outcomes of ischemic stroke during NOAC usage. (time frame: 30 Sept 2021). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Feb 2026.